Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Maze Therapeutics (MAZE) Equity Average (2024 - 2025)

Maze Therapeutics has reported Equity Average over the past 2 years, most recently at $367.2 million for Q4 2025.

  • Quarterly Equity Average rose 223.28% to $367.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $367.2 million through Dec 2025, up 223.28% year-over-year, with the annual reading at $21.9 million for FY2025, N/A changed from the prior year.
  • Equity Average was $367.2 million for Q4 2025 at Maze Therapeutics, up from $320.8 million in the prior quarter.
  • Over five years, Equity Average peaked at $367.2 million in Q4 2025 and troughed at -$333.0 million in Q2 2024.